The Breast 62 2022 S50eS53 Contents lists available ScienceDirect The Breast j o u r n l h o m e p g e w w w e l s e v e r c o m b r s t Axillary surgery nodepositive breast cancer Nadia Maggi b Rahel Nussbaumer b Liezl Holzer c Walter P Weber b Breast Center University Hospital Basel Basel Switzerland b University Basel Basel Switzerland c Department Gynecology University Hospital Zurich Zurich Switzerland r t c l e n f o b s t r c t Article history Received 12 July 2021 Accepted 30 August 2021 Available online 31 August 2021 Keywords Breast cancer Breast surgery Axillary dissection Sentinel lymph node procedure Axillary staging Longterm followup data multicenter phase III noninferiority trials conﬁrmed safety omission axillary dissection selected patients clinically nodenegative sentinel nodepositive breast cancer Several ongoing trials investigate extended eligibility Z0011 protocol adjuvant setting Deescalation axillary surgery patients clinically nodepositive breast cancer currently limited neoadjuvant setting sentinel procedure determine nodal pathological complete response Targeted axillary dissection lowers falsenegative rate sentinel procedure consistently associated low risk axillary recurrence recent singlecenter series Axillary dissection remains standard care patients residual disease neoadjuvant chemotherapy results Alliance A011202 pending The TAXIS trial investigates role tailored axillary surgery patients clinically nodepositive breast cancer novel concept designed selectively remove positive nodes adjuvant neoadjuvant setting 2021 Published Elsevier Ltd This open access article CC BYNCND license http creativecommonsorglicensesbyncnd40 1 Summary The evolution axillary surgery characterized surgical escalation Radical axillary lymph node dissection ALND performed standard patients breast cancer century Since identiﬁcation sentinel nodes 90s ALND performed clinically nodepositive breast cancer cancer sentinel nodes Today learned clinical trials omit ALND patients positive sentinel nodes 12 In situation positive sentinel nodes high risk recurrence axillary radiation increasingly preferred ALND 34 In future answer question omit sentinel procedure patients negative ultrasound 5e8 We answer question omit ALND patients positive sentinel nodes additional risk factors 9e11 Finally ﬁnd ways omit ALND clinically nodepositive breast cancer residual disease neoadjuvant This article published supplement supported St Gallen Oncology Conferences Corresponding author Breast Center University Hospital Basel Spitalstrasse 21 CH4031 Basel Switzerland Email address walterweberusbch WP Weber chemotherapy NACT NCT01901094 upfront surgery setting 12 Current concepts use limited axillary surgery proced ures sentinel procedure determine nodes clear NACT removing 1314 2 Current indications axillary dissection Longterm followup data large phase III non inferiority trials randomizing clinically nodenegative patients positive sentinel nodes group axillary dissec tion compared axillaspeciﬁc treatment pub lished Both ACOSOG Z0011 IBCSG 23e01 trials extremely low rates 2 axillary recurrence showing patients need axillaspeciﬁc treatment 12 ALND considered standard practice clinically node positive breast cancer upfront surgery setting patients residual nodal disease NACT locally advanced inﬂammatory breast cancer 2 positive breast cancer cT34 sentinel nodes gross extranodal disease ALND indicated sentinel nodepositive patients macrometastases undergoing mastectomy positive sentinel node se indicate postmastectomy radiotherapy PMRT irradiation httpsdoiorg101016jbreast202108018 09609776 2021 Published Elsevier Ltd This open access article CC BYNCND license httpcreativecommonsorglicensesbyncnd40 N Maggi R Nussbaumer L Holzer et al Table 1 Current indications axillary lymph node dissection The Breast 62 2022 S50eS53 Clinical setting Type surgery Nodal status Primary axillary surgery procedure Indication ALND After NACT cN0 cN1 cN0 cN1 cN1 SLNB SLNB 2 neg SLN TAD ALND Upfront surgery BCS þWBR Mastectomy cN0 cN1 cN0 cN1 inﬂammatory breast cancer SLNBc ALND SLNB ALND Any residual diseasea Any residual diseasea 3 negative SLNb cid2 3 positive SLN cT34 SLNmacrometastasis PMRT planned NACT ¼ neoadjuvant chemotherapy SLNB ¼ sentinel lymph node biopsy SLN ¼ sentinel lymph node TAD ¼ Targeted axillary dissection ALND ¼ axillary lymph node dissection BCS ¼ breast conserving surgery WBR ¼ breast radiotherapy PMRT ¼ postmastectomy radiotherapy Some centers omit ALND case isolated tumor cells b Some centers omit ALND 3 negative SLN removed c In case 1 2 metastases additional risk factors microscopic extracapsular tumor extension lymphovascular invasion nodal irradiation considered include lymph nodes Table 1 If PMRT performed includes axilla sentinel nodepositive patients require ALND radiation sufﬁce 3 This demonstrated EORTC AMAROS trial promising 10year followup data presented San Antonio Breast Cancer Sympo sium 2018 publication pending 15 In trial clinically nodenegative sentinel nodepositive patients n ¼ 1425 17 underwent mastectomy randomized control group ALND compared axillary irradiation experimental treatment At median followup 10 years axillary recurrence occurred 09 ALND group vs 18 irradiation group Even noninferiority proven statistically clinical point view looking low rates axillary recurrence clinical noninferiority demon strated Therefore cases treatment axilla planned patients population irradiation alternative ALND Patient selection axillary radiation versus observation situation ﬁeld ongoing controversy 3 Can Z0011 eligibility broadened Because limitations ACOSOG Z0011 study series randomized trials initiated validate ﬁndings Z0011 ﬁrst results published In meantime protocol validated prospective observational studies practice changed accordingly coun tries 1617 Therefore randomized trials adjusted focus patients excluded Z0011 In ERCIPC 2012001 SERC trial France included 1855 patients 53 sites ac cording Z0011 2012 2018 started select Z0011 noneligible patients August 2018 9 In SENOMAC trial Sweden countries started focus patients undergoing mastectomy 10 All axillary surgery deescalation studies encountered methodological challenges primarily lack power based lower expected rates events accrual 1e391015 4 Clinically nodepositive breast cancer Clinically nodepositive patients commonly deﬁned occurrence palpable disease time diagnosis Non palpable disease detected solely imaging considered clinically nodepositive imaging nodepositive refers frequent subpopulation clinical practice preoperative ul trasound MRI routinely Both groups jointly categorized biopsyproven nodepositive breast cancer pathologic conﬁrmation malignancy recommended 18 Most patients undergo ALND upfront surgery setting event residual nodal disease NACT The use noninvasive imaging NACT replace axillary surgery In metaanalysis looking reliable imaging determining nodal pathological complete response pCR outcome 2380 patients 13 studies noninvasive imaging NACT compared axillary surgery 19 The study showed axillary pCR 395 9412380 Sensitivity ultrasound MRI PETCT far away reliable terms assessing accurate axillary response NACT 65 60 resp 38 At point microscopic analysis nodes NACT needed determine pCR lymph nodes deescalated axillary surgery current practice A metaanalysis 20 studies including 2217 patients investigated falsenegative rate FNR sentinel node procedure biopsyproven clinically nodepositive patients clinically nodenegative sentinel lymph nodes NACT undergoing backup ALND 13 The FNR 22 FNR decreased 8 negative nodes removed double tracing The MARI procedure selectively marked removed sampled node radio active seed showed FNR 7 With combination techniques selective localization removal clipped node sentinel procedure lowest FNR 2e4 achieved 13 This combination called targeted axillary dissection TAD The prospective SenTa registry study included 473 patients clipped nodes 50 German centers It showed clipped lymph node sentinel node identical 648 detection rate clipped lymph node NACT 869 14 This means clip left 13 pa tients problematic medicallegal aspect case regional recurrence However terms FNR formance FNR 72 removal localized node FNR 43 TAD performed Table 2 The sentinel node procedure NACT clinically node positive patients turned clinically nodenegative NACT Table 2 Deescalating axillary surgery clinically nodepositive breast cancer undergoing NACT 1314 Procedure n patients Identiﬁcation rate FNR SLNB 2002 89 MARI TAD seed TAD seed 95 120 473 97 100 86 Overall 17 3 SNL 22 cid23 SNL 8 7 2e4 43 SLNB ¼ sentinel lymph node biopsy SNL ¼ sentinel lymph node FNR ¼ false negative rate NACT ¼ neoadjuvant chemotherapy MARI ¼ marking axillary positive lymph node iodine seed TAD ¼ targeted axillary dissection S51 N Maggi R Nussbaumer L Holzer et al The Breast 62 2022 S50eS53 Table 3 Deescalated axillary surgery procedure clinically node positivebreast cancer Axillary recurrence nodenegative patients NACT 20e23 First author n patients SLNB median Double tracer Irradiation Axillary recurrence absolute Median followup y Wong KahlerRibeiroFontana Damin Piltin 102 123 38 139 4 2 2 3 Yes No only99Tc Yes NA 71 42 87 78 0 2 1 1 3 92 47 28 commonly performed procedure today For long time importance FNR unclear leaving chemo resistant cancer nodes increase axillary recurrence compared adjuvant setting A retrospective singlecenter study Canada investigated 102 patients setting 20 Of 71 regional irradiation medium 4 negative sentinel nodes removed There single case axil lary recurrence median followup years However authors insisted having negative nodes expected FNR low combination broad use axillary irradiation results expected On hand series Milan reported axillary recurrences long median follow 92 years 123 patients 21 Importantly single tracer 99Tc resulting 74 patients 3 negative sentinel nodes majority patients regional irradiation Hence expected FNR higher vast majority patients recurrence Similar results conﬁrmed retro spective studies Brazil Mayo Clinic removal median 2 3 negative sentinel nodes respectively low rate recurrence 2223 These results conﬁrmed sentinel procedure valid treatment option patients Table 3 5 Ongoing clinical trials clinically nodepositive breast cancer ALND standard procedure residual disease NACT detected sentinel nodes The ongoing Alliance A011202 trial randomizing patient population ALND compared axillary radiation context extended regional nodal irradiation NCT01901094 Accrual completed primary endpoint analysis expected years Until omission ALND considered experimental patients An analysis National Cancer Database looked patients 3 lymph nodes residual disease compared sentinel procedure deﬁned removal cid34 lymph nodes radiation n ¼ 304 versus ALND radiation n ¼ 1313 24 Patients ALND showed worse overall survival 71 vs 77 5 years Even se lection bias studiespatients comorbidities spared ALND difference outcome comorbidity omission ALNDthese results caution conﬁrmation randomized trials Interestingly authors subgroups primarily luminal tumors lymph node metastasis omission ALND decrease survival The European phase III randomized controlled TAXIS trial vestigates role novel concept called tailored axillary surgery TAS patients clinically node positive breast cancer neoadjuvant upfront surgery setting NCT03513614 Accrual running estimated 400 patients randomized total planned sample size 1500 Fig 1 TAS removes palpably clearly suspicious lymph nodes sentinel lymph nodes imagingguided localization clipped node optional Main purpose TAS reduce tumor load axilla point axillary irradiation control Therefore randomized manner TAS axillary irradiation compared standard ALND context irradiation This noninferiority trial extended regional nodal Fig 1 Accrual TAXIS trial The dotted line estimated accrual blue line actual accrual S52 N Maggi R Nussbaumer L Holzer et al The Breast 62 2022 S50eS53 Canc 2018181 httpsdoiorg101186s1288501850537 Available 10 De Boniface J Ahlgren J Andersson Y Bergkvist L Frisell J Lundstedt D et al The generalisability randomised clinical trials interim external validity analysis ongoing SENOMAC trial sentinel lymph nodepositive breast cancer behalf SENOMAC Trialists Group Internet Breast Canc Res Treat httpsdoiorg101007s10549020055371 Available 2020180167e76 11 Goyal A Dodwell D POSNOC randomised trial looking axillary treatment women sentinel nodes macrometastases Internet27 Clinical httpsdoiorg101016 Ltd jclon201507005 cited 2021 Apr 11 pp 692e5 Available Oncology Elsevier 2015 12 Henke G Knauer M Ribi K Hayoz S Gcid1erard MA Ruhstaller T et al Tailored axillary surgery axillary lymph node dissection followed radiotherapy patients clinically nodepositive breast cancer TAXIS study protocol multicenter randomized phaseIII trial Available httpsdoiorg101186s1306301830219 13 Simons JM van Nijnatten TJA van der Pol CC Ejt Luiten Koppert LB Smidt ML Diagnostic accuracy different surgical procedures axillary staging neoadjuvant systemic therapy nodepositive breast cancer Internet Ann Surg 2019 Mar 1 cited 2021 Mar 212693432e42 Available https journalslwwcom0000065820190300000010 14 Kuemmel S Heil J Rueland A Seiberling C Harrach H Schindowski D et al A prospective multicenter registry study evaluate clinical feasibility targeted axillary dissection TAD nodepositive breast cancer patients Ann Surg 2020 Publish Ah 15 Exner R Exner FREBS Post San Antonio Breast Cancer Symposium 2018 Local operative therapy radiotherapy memo Mag Eur Med Oncol Internet Available httpsdoiorg101007s1225401905136 16 Hennigs A Kopke M Feißt M Riedel F Rezai M Nitz U et al Which patients sentinel nodepositive breast cancer breast conservation receive completion axillary lymph node dissection routine clinical practice Internet Breast Canc Res Treat 2019 httpsdoiorg101007s10549018 50092 Jan 30 cited 2021 Apr 111732429e38 Available 17 Morrow M Van Zee KJ Patil S Petruolo O Mamtani A Barrio AV et al Axillary dissection nodal irradiation Be avoided nodepositive z0011 eligible breast cancers prospective validation study 793 patients Internet Ann Surg 2017 Sep 1 cited 2021 Apr 112663457e62 Available frompmcarticlesPMC5649371 18 Macdonald S Oncology R General M Breast cancer breast cancer Internet J R Soc Med 2016708515e7 Available httpswww2trikobeorgnccn guidelinebreastenglishbreastpdf 19 Samiei S Mooij CM Lobbes MBI Keymeulen KBMI van Nijnatten TJA Smidt ML Diagnostic performance noninvasive imaging assessment axillary response neoadjuvant systemic therapy clinically node positive breast cancer systematic review metaanalysis Internet Ann Surg 2021 Apr 1 cited 2021 Mar 212734694e700 Available httpwwwncbinlmnihgovpubmed33201095 20 Wong SM Basik M Florianova L Margolese R Dumitra S Muanza T et al Oncologic safety sentinel lymph node biopsy neoadjuvant chemotherapy breast cancer Internet Ann Surg Oncol 2020 https doiorg101245s10434020092110 Available 21 KahlerRibeiroFontana S Pagan E Magnoni F Vicini E Morigi C Corso G et al Longterm standard sentinel node biopsy neoadjuvant treatment breast cancer single institution tenyear followup Internet Eur J Surg Oncol 2020 httpsdoiorg101016jejso202010014 Apr 1 cited 2021 Apr 7 Available 22 Damin AP Zancan M Melo MP Biazus JV Sentinel lymph node biopsy neoadjuvant chemotherapy patients nodepositive breast cancer guiding selective axillary approach vol 186 2021 p 527e34 https doiorg101007s10549020060118 Available 23 Piltin MA Hoskin TL Day CN Davis J Boughey JC Oncologic Outcomes Sentinel Lymph Node Surgery After Neoadjuvant Chemotherapy Node Positive Breast Cancer Available httpsdoiorg101245s10434020 089000 24 Almahariq MF Levitin R Quinn TJ Chen PY Dekhne N Kiran S et al Omission axillary lymph node dissection associated inferior survival breast cancer patients residual N1 nodal disease following neoadjuvant chemotherapy Internet Ann Surg Oncol 202128930e40 httpsdoiorg 101245s10434020089282 Available investigates diseasefree survival primary endpoint quality life important secondary endpoint Completion accrual expected 2024 analysis primary endpoint published 2030 Declaration competing No commercial support provided study All authors WP Weber disclose Outside submitted work WP Weber received research support Takeda Phar maceuticals International paid Swiss Group Clinical Cancer Research SAKK personal honoraria Genomic Health Inc USA Support meetings paid institution Sandoz Genomic Health Medtronic Novartis Oncology Pﬁzer Eli Lilly References 1 Galimberti V Cole BF Viale G Veronesi P Vicini E Intra M et al Axillary dissection versus axillary dissection patients breast cancer sentinelnode micrometastases IBCSG 2301 10year followup rand omised controlled phase 3 trial Internet Lancet Oncol 2018 Oct 1 cited 2021 Mar 2119101385e93 Available httpwwwthelancetcom articleS1470204518303802fulltext 2 Giuliano AE Ballman KV Mccall L Beitsch PD Brennan MB Kelemen PR et al Effect axillary dissection vs No axillary dissection 10year overall sur vival women invasive breast cancer sentinel node metas tasis ACOSOG Z0011 alliance randomized clinical trial HHS public access J Am Med Assoc 201731810918e26 3 Donker M van Tienhoven G Straver ME Meijnen P van Velde CJH Mansel RE et al Radiotherapy surgery axilla positive sentinel node breast cancer EORTC 1098122023 AMAROS randomised multi centre openlabel phase 3 noninferiority trial Internet Lancet Oncol 2014 Nov 1 cited 2021 Mar 2115121303e10 Available frompmcarticles PMC4291166 Internet 4 Scid1avolt Pcid1eley G Polgcid1ar C Udvarhelyi N Rubovszky G Kovcid1acs E et al Eightyear follow result OTOASOR trial Optimal Treatment Axilla e surgery Radiotherapy positive sentinel lymph node biopsy early stage breast cancer randomized single centre phase III noninferiority trial httpsdoiorg101016 jejso201612011 Apr 1 cited 2021 Apr 11434672e9 Available 5 Hughes KS Schnaper LA Bellon JR Cirrincione CT Berry DA McCormick B et al Lumpectomy plus tamoxifen irradiation women age 70 Years older early breast cancer longterm followup CALGB 9343 Internet J Clin Oncol 2013 cited 2021 Apr 11312382e7 Available wwwjcoorg Surg Oncol 2017 Eur J 6 Gentilini O Botteri E Dadda P Sangalli C Boccardo C Peradze N et al Physical function upper limb breast cancer surgery Results SOUND Sentinel node vs Observation axillary UltrasouND trial Internet Eur J Surg Oncol 2016 httpsdoiorg101016jejso201601020 May 1 cited 2021 Apr 11425685e9 Available 7 Reimer AT Stachs A Nekljudova V Loibl S Hartmann S Wolter K et al Restricted axillary staging clinically sonographically nodenegative early invasive breast cancer ciT12 context breast conserving therapy ﬁrst results following commencement intergroupsentinel mamma INSEMA trial eingeschra Axillary Staging Geburtsh Frauenheilk Internet 201777149e57 Available httpdx 8 Van Roozendaal LM Vane MLG Van Dalen T Van Der Hage JA Strobbe LJA Boersma LJ et al Clinically node negative breast cancer patients undergoing breast conserving therapy sentinel lymph node procedure versus followup Dutch randomized controlled multicentre trial BOOG 201308 Available httpsclinicaltrialsgovct2showNCT02271828 9 Houvenaeghel G Cohen M Raro P De Troyer J De Lara CT Gimbergues P et al Overview pathological results treatment characteristics ﬁrst 1000 patients randomized SERC trial axillary dissection versus axillary dissection patients involved sentinel node Internet BMC S53